Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 5
2006 1
2008 2
2009 2
2010 5
2012 3
2013 5
2014 4
2015 6
2016 5
2017 4
2018 2
2019 2
2020 7
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Animal-free applications in the development of cell-based therapies.
van Meer P, Theunissen P, van den Hoorn T, Herberts C, van der Laan JW. van Meer P, et al. Among authors: van der laan jw. Br J Clin Pharmacol. 2020 Sep 15. doi: 10.1111/bcp.14544. Online ahead of print. Br J Clin Pharmacol. 2020. PMID: 32935350 No abstract available.
A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals.
Luijten M, Corvi R, Mehta J, Corvaro M, Delrue N, Felter S, Haas B, Hewitt NJ, Hilton G, Holmes T, Jacobs MN, Jacobs A, Lamplmair F, Lewis D, Madia F, Manou I, Melching-Kollmuss S, Schorsch F, Schütte K, Sewell F, Strupp C, van der Laan JW, Wolf DC, Wolterink G, Woutersen R, Zvonar Z, Heusinkveld H, Braakhuis H. Luijten M, et al. Among authors: van der laan jw. Regul Toxicol Pharmacol. 2020 Dec;118:104789. doi: 10.1016/j.yrtph.2020.104789. Epub 2020 Oct 7. Regul Toxicol Pharmacol. 2020. PMID: 33035627 Free article. Review.
Is current risk assessment of non-genotoxic carcinogens protective?
Braakhuis HM, Slob W, Olthof ED, Wolterink G, Zwart EP, Gremmer ER, Rorije E, van Benthem J, Woutersen R, van der Laan JW, Luijten M. Braakhuis HM, et al. Among authors: van der laan jw. Crit Rev Toxicol. 2018 Jul;48(6):500-511. doi: 10.1080/10408444.2018.1458818. Epub 2018 May 10. Crit Rev Toxicol. 2018. PMID: 29745287 Review.
Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.
Giannakou C, Park MVDZ, Bosselaers IEM, de Jong WH, van der Laan JW, van Loveren H, Vandebriel RJ, Geertsma RE. Giannakou C, et al. Among authors: van der laan jw. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Sep;12(5):e1633. doi: 10.1002/wnan.1633. Epub 2020 Apr 7. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020. PMID: 32266791 Free PMC article. Review.
Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals.
Heusinkveld H, Braakhuis H, Gommans R, Botham P, Corvaro M, van der Laan JW, Lewis D, Madia F, Manou I, Schorsch F, Wolterink G, Woutersen R, Corvi R, Mehta J, Luijten M. Heusinkveld H, et al. Among authors: van der laan jw. Crit Rev Toxicol. 2020 Oct;50(9):725-739. doi: 10.1080/10408444.2020.1841732. Epub 2020 Nov 25. Crit Rev Toxicol. 2020. PMID: 33236972
A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.
Yauk CL, Harrill AH, Ellinger-Ziegelbauer H, van der Laan JW, Moggs J, Froetschl R, Sistare F, Pettit S. Yauk CL, et al. Among authors: van der laan jw. Regul Toxicol Pharmacol. 2020 Feb;110:104526. doi: 10.1016/j.yrtph.2019.104526. Epub 2019 Nov 11. Regul Toxicol Pharmacol. 2020. PMID: 31726190
Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective.
van der Laan JW, van Malderen K, de Jager N, Duarte D, Egger GF, Lavergne F, Roque CG, Vieira I, Wiesner L, Carleer J. van der Laan JW, et al. Int J Toxicol. 2019 Nov/Dec;38(6):456-475. doi: 10.1177/1091581819883569. Epub 2019 Oct 29. Int J Toxicol. 2019. PMID: 31662008
Mining scientific advice reports on cell-based products: Insight into the nonclinical development program.
van den Hoorn T, Nakchedi T, de Wolf ACMT, Pasmooij AMG, van der Laan JW, Herberts CA. van den Hoorn T, et al. Among authors: van der laan jw. Br J Clin Pharmacol. 2020 Aug 13. doi: 10.1111/bcp.14515. Online ahead of print. Br J Clin Pharmacol. 2020. PMID: 32790909
Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018.
van der Laan JW, Benson CT, Janssens W, Bos J, Stahl E, Brady JT, Wändel-Liminga U, Corriol-Rohou S, Forster R, Hartmann A, Pertel PE, Robertson SM, Silva-Lima B, Malik RE, Chibout SD. van der Laan JW, et al. Ther Innov Regul Sci. 2020 Mar;54(2):462-467. doi: 10.1007/s43441-019-00077-3. Epub 2020 Jan 6. Ther Innov Regul Sci. 2020. PMID: 32072587
Challenges and approaches for the development of safer immunomodulatory biologics.
Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, Green J, Griffiths CE, Holgate S, Jones D, Kimber I, Moggs J, Naisbitt DJ, Pirmohamed M, Reichmann G, Sims J, Subramanyam M, Todd MD, Van Der Laan JW, Weaver RJ, Park BK. Sathish JG, et al. Among authors: van der laan jw. Nat Rev Drug Discov. 2013 Apr;12(4):306-24. doi: 10.1038/nrd3974. Nat Rev Drug Discov. 2013. PMID: 23535934 Free PMC article. Review.
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback